Online programme to help diabetes patients

pharmafile | September 14, 2012 | News story | Medical Communications, Sales and Marketing |  Boehringer, diabetes, lilly 

Boehringer Ingelheim and Eli Lilly have launched an online initiative which they say will help diabetes sufferers make simple lifestyle changes to manage their condition.

The so-called ‘beyond pill’ programme is designed to help patients set small goals in areas such as better eating and taking exercise, which will in turn – at least this is the idea – lead to them making even more significant changes in time.

People with type 2 diabetes can register for free and create their own My Well Planner account at www.mywellplannerinfo.com and then take a self-assessment to see how motivated they are.

This allows goals to be personalised – breaking old habits and creating new ones – with progress reports which patients can print out and take to their doctor to discuss during appointments.

Advertisement

While medication is important in treating type 2 diabetes, healthy diet and exercise are also key when it comes to successfully controlling blood glucose levels.

“There is no one-size-fits-all approach to managing type 2 diabetes,” said David Pass, vice president, metabolism marketing, Boehringer.

The combination of online activity and treatment is an obvious one that is being tapped into increasingly by health authorities keen to take pressure off existing services by encouraging self-help.

An estimated 366 million people have diabetes, with type 2 accounting for up to 95% of all cases – and that number is set to grow as more people live sedentary lifestyles and eat unhealthily.

It is also a good fit for the companies: Boehringer and Lilly co-market diabetes treatments Tradjenta (linagliptin) and Jentadueto (linagliptin/metformin hydrochloride) tablets.

About 25.8 million Americans – 8.3% of the population – have diabetes at present and the Centers for Disease Control and Prevention projects that one in three US adults could have diabetes by 2050, if current trends continue.

Adam Hill

Related Content

Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison

Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose …

First 90 days of antipsychotic treatment linked to rapid metabolic changes

The first 90 days after starting antipsychotic treatment are a critical period for monitoring blood …

Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial

Boehringer Ingelheim’s investigational survodutide produced weight loss of up to 13.1% after 76 weeks in …

The Gateway to Local Adoption Series

Latest content